Financials
- Fiscal year
- 2025
- Total assets
- €2.3m
- Profit
- €163,718
- Solvency
- 32.1%
Total assets▲ 1.9%
Net result
20182025
Solidpharma
ActiveSummary
Solidpharma has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €733,170 and a net result of €163,718. Equity is shrinking by ~3.7% per year across the filed fiscal years. Its solvency ranks better than 45% of 12396 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Overview
Activity
Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses
NACE 47741Wholesale of pharmaceutical and medical goods NACE 46460NACE 47740
1 site
Size
€2.3mtotal assets 2025
- Staff
- 6 FTE
- Equity
- €733,170
- Profit
- €163,718
Turnover not published (abridged schema)
Structure
- Parent
- Namalno · 100%
Accounts filed 3 d late0 of 9 deeds read
Why 87- Sector Retail trade (NACE 47)+ Founded in 2010+ Figures for FY 2025 (filed 05-01-2026)+ Liquidity: current ratio 1.30, cash €296,454Show the evidence
Checked score
Score 2025
87
/ 100
Excellent
Probability in this band: under 0.55%
Better than 56% of its sector peers (NACE 47, micro)
Performance against the sector, not lower risk
Financial strength · tick = 2024
Average
Solvency
57+7
equity 32.1% of total assets
Liquidity
34+12
short-term debt 62.1% · cash 13.0%
Profitability
78+21
return on assets 7.2%
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.6%
12-2024: 0.7%▲ +25.8% vs 11-2024
01-2025: 1.2%▲ +64.0% vs 12-2024
02-2025: 0.8%▼ -31.2% vs 01-2025
03-2025: 0.8%● 0.0% vs 02-2025
04-2025: 0.8%● 0.0% vs 03-2025
05-2025: 0.8%● 0.0% vs 04-2025
06-2025: 0.8%▼ -0.7% vs 05-2025
07-2025: 0.8%● 0.0% vs 06-2025
08-2025: 0.8%▼ -2.4% vs 07-2025
09-2025: 0.8%▼ -5.5% vs 08-2025
10-2025: 0.8%▲ +1.2% vs 09-2025
11-2025: 0.8%▲ +4.8% vs 10-2025
12-2025: 1.1%▲ +34.5% vs 11-2025
01-2026: 1.7%▲ +60.3% vs 12-2025highest value
02-2026: 0.2%▼ -86.8% vs 01-2026lowest value
03-2026: 0.2%● 0.0% vs 02-2026lowest value
04-2026: 0.2%● 0.0% vs 03-2026lowest value
05-2026: 0.2%● 0.0% vs 04-2026lowest value
06-2026: 0.2%● 0.0% vs 05-2026lowest value
07-2026: 0.2%▲ +5.2% vs 06-2026
08-2026: 0.2%● 0.0% vs 07-2026
09-2026: 0.3%▲ +10.7% vs 08-2026
10-2026: 0.3%▲ +1.1% vs 09-2026
- Founded in 2010 lowers the probability for this profile
- Figures for FY 2025 (filed 05-01-2026) lowers the probability
- Sector Retail trade (NACE 47) raises the probability
- Liquidity: current ratio 1.30, cash €296,454 lowers the probability
Credit up to €60,000 at 30 days acceptable
Liquidity tight (current ratio 1.3 against 1.06 in 2024; short-term debt: 62.1% and cash: 13% of total assets), and 67.9% of the assets are financed with debt.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 47, micro). Better than this share of them on solvency 48%, liquidity 31%, profitability 67%, growth against the median 79%. That is performance, not lower risk; the band itself always comes from the probability.
Bankruptcy probability: model pd-v3.202610021621, computed on 05-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
18192021232425
2018 to 2025 · latest year €733,170
neutral · Filed after the deadline
The financial year that closed on 31-05-2025 was due by 31-12-2025 and was filed on 03-01-2026, 3 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
3 d late
2024
6 d late
2023
3 d late
2021
31 d late
2020
30 d late
2019
77 d early
2018
55 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 8 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-05-2026 and is due by 31-12-2026. Nothing is late today. Usually files around 3 January (3 of the last 3 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
31-05-2026 close06-10-2026 today31-12-2026 deadline
- Annual accounts filedfiscal year 2025 · abbreviated…
- Annual accounts filedfiscal year 2024 · abbreviated…
- Weakest financial yearnet €14,558 ▼93.6%
Key points
- Positive: Result rose in 2025from €14,558 to €163,718 ▲ 1,025% View
- Positive: Among the best 15% on net resultsector median €28,387 · 12,384 companies €163,718 View
- Controlled by Namalno 100% View
- Positive: 7 profitable years in a rowprofit 2025: €163,718 7 years View
- Flemish supportawarded 2022 - 2025 €61,939 View
By topic
Board & ownership
- Parent
- Namalno · 100%
Timeline
- Events
- 14
- Since
- 2016
- Next accounts
- by 31-12-2026
- 03-01-2026Annual accounts filed
- 06-01-2025Annual accounts filed
- 31-05-2024Weakest financial year
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Retail sale of medical and orthopaedic goods, excluding…NACE 47741
- Founded
- 19-05-2010
- Year ends
- 31-05
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Subsidies How does this company compare with its sector?Sector benchmark
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.